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Abstract 
Boron Neutron Capture Therapy (BNCT) is a binary form of experimental radiotherapy which is based on the administration of a 
drug able to concentrate the isotopes in a tumor cell that later are irradiated with a neutron beam. Even though the first evidence 
of the success of this treatment dates back many years ago, BNCT showed successful treatment results in malignant melanoma, 
and Glioblastoma. In order for BNCT to be successful, a sufficient amount of Boron (10B) must be selectively delivered to the 
tumor cell, and then irradiated by neutrons of sufficient enough. The CS-30 cyclotron at King Faisal Specialist Hospital & 
Research Center is a positive-ion machine capable of accelerating protons at 26MeV, and other isotopes as well. Although the 
peak beam intensity from the CS-30 is low, the key to success of using it for the BNCT is by using a high average beam current 
at low energy. This work is aimed at testing the capability of the CS-30 Cyclotron to produce a low-energy neutron beam to be 
used to activate the Boron atoms injected into the tumor cell, through simulation of a compatible moderator. We are also 
planning to measure the overall dosimetry of the energy dose as well as that for the boron in the tumor cell. 
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1. Introduction 
This paper discusses a preliminary experiment idea for cancer treatment in the Kingdom of Saudi Arabia, where 
we intend to use the cyclotron located at the King Faisal Specialized Hospital to produce a neutron beam with 
specific energy suitable for Boron Neutron Capture Therapy, BNCT. A brief history and discussion of BNCT is also 
presented and follows: 
Chadwick discovered the neutron in 1932 (Breithaup 2000) and the use of neutrons in the field of radiotherapy as 
a development for cancer treatment appeared afterwards (Kageji et al 2011). In 1938, Lawrence Berkeley 
Laboratory demonstrated neutron radiotherapy through a number of experiments (Stone 1948). Later on, a number 
of new treatments using neutrons in both scientific and medical applications (Dagrosa 2007) such as Boron Neutron 
Capture Therapy (BNCT), for the treatment of cancer tumors were recognized by Locher from a theoretical 
prospective. In 1951 this treatment was used on interclincal tumors (Harling 2000). The researchers were working 
hard to find the best way to use neutrons for such a treatment, and afterwards scientists found that the use of 10B 
through irradiation with a beam of neutrons with a specific energy would be an effective treatment (Zahl 1940). The 
first treatment of humans dates back to 1953 (Soloway 1967, Godwin 955) where 10 patients were treated but there 
were some side effects due to immature technology in several fields such as radiation dosimetry. Research has 
continued (Farr 1954), and the number of countries now pursuing BNCT as a viable cancer treatement technique has 
increased. Between 2001 and 2011, 165 patients have been treated using this kind of therapy in Japan, the USA, and 
Europe (Pinelli 2001, Porcari 2009, Hosmane 2011). 
Boron neutron capture therapy, is still considered an experimental radiotherapy: It is based on the intravenous 
infusion of boron into the patient’s bloodstream, and uptake of boron by the cancer cells of the tumor site. The 
administration of this drug helps in increasing the concentration of the isotope 10B in the cancer cells which 
subsequently is irradiated with an external dose of low energy neutrons.  
The boron delivery agent is a non-toxic and non-radioactive drug designed to concentrate in the cells affected by 
cancer. The tumor cells will have a high concentration of boron while the normal tissue will not. In response to the 
irradiation of the target cells with neutrons with specific energy, the boron captures these neutrons and produces 
high linear-energy-transfer (LET) alpha and lithium particles. These particles have a range in tissue of about 5-9 Pm 
which is equivalent to the diameter of the cell nucleus. Thus high LET released in the tumor cells is able to destroy 
and kill the cell without damaging neighboring healthy tissue. This process of radiotherapy increases the effect of 
the radiation dose that the patient receives at the tumor site by a factor of 2 or even 3, limiting damage of the 
surrounding cells (Riely 2008). 
 
The basic components of the BNCT radiotherapy are as follows: 
x Take advantage of naturally-occuring 10Boron isotopes (20% of elemental boron). 
x Uses an optimized 10Boron carrier/delivery agent ratio (Burian 2004, Keunen 2011). 
x 10Boron compounds that are selectively absorbed by tumor cells are available. 
x Requires a specific neutron beam energy spectrum (thermal/epithermal) to irradiate tumor cells (see, Fig. 1). 
x Takes advantage of measured 10Boron absorption cross sections. 
x Uses the following (10B, n) reactions to produce energetic alpha and Lithium particles (Nigg 1999) to destroy the 
cancer cells: 
        10B + nth Æ4He + 7Li + 2.79 MeV (6%)                                                                                                           (1) 
10B + nth Æ4He + 7Li + 2.31 MeV + J 0.48 MeV (39.9%)                                                                               (2)                
 
The primary prerequisite for a successful BNCT treatment is having the correct amount of boron isotopes 
deposited in the tumor cells relative to the boron concentration in the normal tissue. In addition, sufficient 
neutron energy to induce the reactions (1) and (2) above is another crucial factor in BNCT therapy as well.  
Even though, there are many treatments for cancer, such as surgery, chemotherapy and more conventional 
radiation therapy, not all are effective for all types of cancer tumors (Lowry 1975, Khan 1994), so the search for 
an effective and more sufficient treatment must be developed. There are a certain number of cancer tumors that 
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resist some of the above mentioned therapies, for example Glioblastomas of the brain, Melanomas and Malignant 
(Cunnighanet 1983, Selman 1960 , Harling 2009). 
 BNCT is an effective and promising treatment for different types of cancer because it delivers a high-
radiation dose in a selective way to cancer cells (Barth 1994, Coderre 2003, Hickey 2010). However, BNCT is 
still in the development stage and not yet widely used in hospitals.  Contributing factors that limit wide-spread 
use include the following: 
x The significant cost and size of the nuclear reactors presently required to produce the neutron beam 
x The significant safety requirements for manipulation of radioactive materials. 
 
 For the above reasons, recent research activities world-wide have changed their focus to the development of 
BNCT accelerators that are smaller in size, less costly, environmentally friendly, safer, and can be installed in 
hospitals with ease compared to nuclear reactors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Neutron Source 
In 1975, the King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia was fully equipped and 
ready for the treatment of patient. Later the associated Research Center (KFSH-RC) was established with the goal of 
providing excellent patient care in the field of cancer treatments. Even though radiation therapy was provided by the 
hospital, ways to enhance this capability locally were sought; the most efficient way to do so was by acquiring a 
cyclotron. In 1982, the Cancer Therapy Institute became operational at the KFSH-RC, and a CS-30 medical 
cyclotron produced by the Cyclotron Corporation in Berkeley, California (Laughlin 1974) was installed. This 
cyclotron is shown in Fig. 2 and is able to accelerate different particles to produce different beam currents, and beam 
energies as needed: Table 1 below summarizes the available Cs-30 beam parameter options. 
      Table 1.  Particles Accelerated by KFSH-RC cyclotron with their energy and beam current. 
Particles Beam Current 
Internal 
Beam Current 
Extracted 
Protons               26 MeV 200 PA 60 PA 
Deuterons          15 MeV 300 PA 100 PA 
Helium3             38 MeV 135 PA 60 PA 
Helium4             39 MeV 90 PA 40 PA 
 
Fig. 1. Boron Neutron Capture Therapy Fig. 2. CS-30 Cyclotron at KFSH-RC. 
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    The cyclotron facility layout is shown in Fig. 3. The design of this cyclotron is unique, since it has the capability 
to produce neutrons with two different energies by accelerating either deuterons or protons and scattering from a 
sent towards a Be target. Figure. 3. From Fig. 4, shows the seven available beam lines; 
 x Research beam line with 101.5º analyzing magnet. x Radiogas system. x Isorabbit target system. x Isorabbit target system. x Manual load, remote unload target. x Isocentric neutron therapy. x Liquid gas or metal target system. 
The isocentric neutron therapy system has been designed to allow either deuterons or protons to bombard the Be 
target in order to produce neutrons. It is this beam line that is being developed for BNCT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Previous work at KFSH-RC 
In 1984, fast neutron radiotherapy became available at KFSH-RC. This kind of therapy is also a new technique 
for the treatment of specific types of cancer tumors, where energetic neutrons lose energy that is deposited in the 
atomic nuclei of the medium. At energies above tens of MeV, neutrons interact with matter via inelastic nuclear 
reactions and give birth to heavy particles and gamma radiation. The charged particles lose energy along their track 
(LET, Linear Energy Transfer), with a dramatic increase before the point where they come to rest. This is known as 
the Bragg peak (Wilson 1946). The biological damage is related to the LET (ICRP 2007, ICRUM 2012) and the 
absorbed dose. Furthermore, the absorbed dose and the Relative Biological Effectiveness (RBE) are key factors in 
the dosimetery of clinical neutron therapy. The study of the dose distribution as a function of the LET of the neutron 
beam produced by the KFSH-RC cyclotron took place in 1991, aiming to measure: 
 
x The LET spectrum. 
x Quantity of the therapeutic neutron beam through the examination of the energy deposition by charged 
particles in a water phantom that simulated a tissue volume. 
x Changes in the dose distribution. 
x Evaluate radiation quality with water phantom depth and lateral distance from the beam axis.  
 
The neutron source for this study was a therapeutic neutron beam produced by the 26-MeV proton (KFSH-RC 
cyclotron) - beryllium reaction. 
Fig. 3. Be target. Fig. 4. The Layout of Cyclotron Facility at KFSH-RC. 
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The measurements were done in a water phantom, 40 cm x 40 cm x 30 cm with 20-cm water depth, at different 
distances from the beam axis and different lateral distances. Also, these measurements were taken at the surface of 
the water phantom in free air. Moreover, the data was analyzed to evaluate the RBE of the neutron beam at all points 
of measurements. 
 
4. Results 
    
   Absorbed dose and relative biological effectiveness (RBE) of the neutron beam is an essential factor in clinical 
radiotherapy applications. In addition, in neutron therapy it is important to assess the radiation quality of the beam, 
since neutrons have high LET compared to other particles. Thus, the LET spectra can be used to estimate the 
radiation quality. The measured spectra are pulse-height spectra that are converted into lineal energy (Y), which is 
the quotient energy, E/d, where E is the energy deposited to matter in a volume during an energy deposition event, 
and d is the mean chord length in the volume of interest. In order to obtain high resolution over the entire spectrum, 
the spectra should be measured in several segments. The data was obtained to determine: 
 x The relationship between fractional dose D(Y) versus lineal energy transfer Y. x The relationship between weighted fractional dose versus Y. x The relationship between REB x Y D(Y) versus Y. 
Fig. 5 shows the variation of Y D(Y) vs. Y along the beam axis at different depths in the water phantom, where 
the changes in the LET spectrum are quite small. At high energy there is a small decrease in Y D(Y) with depth. Fig. 
6 illustrates Y D(Y) vs. Y at different distances off the beam axis for different depths in the water phantom. In this 
Fig there is an increase in Y D(Y) near the proton beam edge for all depths due to the scattering of neutrons that 
produce high LET recoil protons. Figures 7 and 8 represent Y D(Y) variation at different lateral distances. There is 
an increase in Y D(Y) near the beam edge and outside the beam Y D(Y). Figure 9 shows Y D(Y) vs. Y in air for 
different distances off the beam axis, whereas there is no increase outside the beam Y D(Y) according to the water 
phantom data. Figures 10 and 11 shows RBE x Y D(Y) vs. Y in free air for different lateral distances off the beam 
axis. Figures 12 and 13 shows RBE x Y D(Y) vs. Y on the beam axis for the different depths in the water phantom. 
The values of the mean lineal energy dose for all spectra at different spatial positions are reported in Table 2. 
Table 3 represents the calculated values of the RBE for all spectra at different spatial positions at three survival 
levels. Fig. 14 shows the variation of dose rate vs. lateral distance in the beam axis for 5-cm depths in the water 
phantom. Table 4 represents the absorbed dose values at different spatial positions in the water phantom for the 
therapeutic neutron beam. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Micrrodosimeteric spectra measures in the beam     
axis for different depths in water phantom.                
Fig. 6. Microdosimeteric spectra at 5cm off beam axis in water 
phantom for different depths. 
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Fig. 7. Microdosimetric spectra measured at 0.5 cm depth in 
water phantom for different lateral distances in the beam axis.           
Fig. 8. Microdosimetric spectra measured at 15 cm depth in water 
phantom for different lateral distances off the beam axis. 
Fig. 9. Microdosimetric spectra in air for different distances 
off the beam axis. 
Fig. 10. RBE * YD(Y) vs. Y in the beam axis in air. 
Fig. 11. RBE * YD(Y) vs. Y at 5 cm off  the beam axis in 
air. 
Fig.12. RBE * YD(Y) vs. Y at 0.5 cm depth in water 
phantom. 
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    Table 2.  Variation of relative biological effectiveness for different spatial positions (cm) in water phantom and in air. 
LAT. DIST. 
Depth 
0.00 5.00 6.00 7.00 9.00 Cell Survival 
 
0.5 
3.51 
2.29 
1.79 
3.59 
2.33 
1.81 
3.72 
2.39 
1.85 
3.88 
2.54 
1.98 
3.97 
2.63 
2.05 
80% 
10% 
1% 
 
5.00 
 
3.59 
2.33 
1.82 
3.58 
2.31 
1.87 
3.75 
2.43 
1.88 
3.96 
2.56 
1.98 
4.07 
2.66 
2.07 
80% 
10% 
1% 
 
10.00 
3.55 
2.30 
1.79 
3.55 
2.30 
1.79 
3.57 
2.31 
1.79 
3.89 
2.51 
1.94 
3.91 
2.56 
1.99 
80% 
10% 
1% 
 
15.00 
3.55 
2.29 
1.77 
3.56 
2.31 
1.80 
3.70 
2.39 
1.85 
4.03 
2.59 
1.99 
4.09 
2.65 
2.04 
80% 
10% 
1%A 
 
Air 
3.54 
2.29 
1.78 
3.51 
2.28 
1.78 
3.49 
2.27 
1.77 
4.04 
2.59 
1.98 
4.05 
2.60 
1.99 
80% 
10% 
1%A 
 
 
 
Fig. 13. RBE * YD(Y) vs. Y at 0.5cm depth and 9cm off beam 
axis. 
Fig. 14. Beam profile of neutron for field size 10 x 10 cm2in 
water phantom. 
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    Table 3.  Variation of Dose with position in water phantom. 
Lateral Distance 
(cm) 
 
0.5 
 
5.00 
 
6.00 
 
7.00 
 
9.00 
 
5             
 
100(with depth) 
.2269 
100(lateral 
Distance) 
100(with 
depth) 
.1949 
68(lateral 
Distance) 
100(with 
depth) 
.0942 
41(lateral 
Distance) 
100(with 
depth) 
.0393 
17(lateral 
Distance) 
100(with 
depth) 
.0223 
9.8(lateral 
Distance) 
      
10 
 
70(with depth) 
.1593 
100(lateral 
Distance) 
69(with 
depth) 
.1341 
84(lateral 
Distance) 
85(with 
depth) 
.0807 
51(lateral 
Distance) 
98(with 
depth) 
.0384 
24(lateral 
Distance) 
85(with 
depth) 
.01909 
12(lateral 
Distance) 
           
15 
 
43(with depth) 
.09682 
100(lateral 
Distance) 
42(with 
depth) 
.08192 
83.4(lateral 
Distance) 
61(with 
depth) 
.05792 
59(lateral 
Distance) 
77(with 
depth) 
.03047 
31(lateral 
Distance) 
82(with 
depth) 
.0184 
19(lateral 
Distance) 
 
 
5. Conclusion 
 
   The measurements made through this study using a neutron beam produced using the CS-30 cyclotron at KFSH-
RC are in a good agreement with the theoretical and experimental expectations. Using this past work, we have 
characterized the radiation quality of fast neutron beams as well as the dose distribution in water phantom. In fact, it 
was observed that with the increase of depth, the total dose decreases and with lateral distance, this occurs due to 
neutron attenuation. The different dose distribution measured in this work shows that the dose contribution of D -
particles and heavy recoil ions to the neutron dose that increases at the beam center and decreases at its edge. At 100 
KeV/Pm energy deposition, most LET distribution show a sharp edge due to the maximum LET value that the 
proton can have. In addition, fast neutrons (up to 15 KeV/Pm) produces J-rays and recoil protons that appear at the 
front part of the LET distribution.  
    In a given biological system the dose delivered effects the level of damage in the surrounding tissues, where the 
RBE varies accordingly. The RBE is directly proportional to the LET, peaking at 100 KeV/mm as showed in 
previous figures. On the other hand, RBE does not vary with depth. At the edge of the beam the RBE increases due 
to the increase in the number of scattered neutrons (low energy), that have high-LET recoil proton. Another peak 
appears due to the recoil ions produced by slower neutrons. At the beam axis the value of the RBE calculated is in a 
good agreement with previous work (Calkins 1989). From the beam line axis to the edge of the beam line the dose 
mean lineal energy increases in both a water phantom and air, and is then observed to decrease outside of the beam 
as shown in Table 2. All measurements and data from this work will be helpful for using the clinical neutron therapy 
beam at KFSH-RC. 
6. Outlook 
    This project aims to provide the Saudi Arabian society with the most advanced technology in fighting tumors. The 
King Faisal Specialized Hospital and Research Center are looking for valuable partners to accomplish this project 
and start BNCT. Our hope is also to provide a good environment and the opportunity for researchers in medical 
physics and biophysics to work together with particle physicists to develop this research field. 
 I. Badhrees et al. /  Physics Procedia  66 ( 2015 )  59 – 67 67
   Due to aging equipment and facilities, the proton beam currents extracted from the cyclotron today are in the range 
of 10 to 20-PA. The neutron flux for BNCT will be generated by bombarding a beryllium target with a proton beam 
energy of 26.5-MeV. For that we need to design a special target holder for the beryllium that will be well cooled. 
The resulting beam must be tailored in energy and collimation in order to be suitable for BNCT. A beam-shaping 
assembly must also still be designed. The main goal of future work is to develop the system needed on the cyclotron 
beam line to offer a new treatment for tumor treatement in the near future. The BNCT was used for the first time on 
humans in the US using thermal neutron beam (Godwin 1955, Soloway 1967), while in Japan current trials used 
both thermal and epithermal neutron beams (Savolainen 2012). The use of BNCT is beginning to be realized in 
many nations. It can also be realized in Saudi Arabia 
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